The research and development of cellular immune therapy for a variety of diseases is the main business of Creative Biolabs, including the international leading CAR-T design construction cell therapy and TAR-T design construction cell therapy, Creative Biolabs offers programming CAR technologies and transfection technologies for you to chose, our targets cover blood tumors entity related diseases such as cancer and virus infection, we are committed to establishing the domestic and foreign leading technology research and development platform.
Several steps are required for the production of CAR-T or TCR-T T cells. We are able to conduct quality control test throughout the entire protocol.
Fig.1 Cellular therapy has several pathways to the patient.
Easily provide an anti-CD3 or anti-CD28 monoclonal antibody, which is an effective drug to activate T cells
We offer IL-2 and IL-15 cytokine that activate NK cells, which leads to activation of JAK/STAT, PI3K, MAPK, and NF-κB pathways.
✔ IL-2 stimulates cellular proliferation and enhances cytotoxicity
✔ IL-15 significantly improves NK cell survival although it only stimulates minimal expansion
Fig.2 Cytokine activated NK cells.
Macrophages have a unique ability to penetrate solid tumors, while T cells and other immune cells are rejected or inactivated.
✔ CD47 is a negative regulator of phagocytosis, figuring that shifting the balance in favor of macrophage activation and engulfment is a promising therapeutic avenue.
✔ CARPMegf10 initiates engulfment through a localized signaling cascade involving tyrosine phosphorylation.
✔ Megf10 and FcRV robustly trigger engulfment independently of their native extracellular domain.
✔ CD3z of intracellular signaling domains activate engulfment.
Please feel free to contact us and our team will contact you as soon as possible.
For Research Use Only | Not For Clinical Use